EOCN Stock Forecast: Eocene Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Eocene Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (54): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (9): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
EOCN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on EOCN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Apr 2025 | Maxim Group | Downgrade | Hold | — |
| 24 July 2023 | Maxim Group | Upgrade | Buy | — |
| 8 Aug 2022 | Canaccord Genuity | Downgrade | Hold | — |
| 8 Aug 2022 | Maxim Group | Downgrade | Hold | — |
| 18 May 2022 | Raymond James | Downgrade | Market Perform | — |
| 3 May 2022 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 3 May 2022 | Raymond James | Maintains | Outperform | — |
| 17 May 2021 | Canaccord Genuity | Maintains | Buy | — |
| 19 Mar 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Jan 2021 | Raymond James | Maintains | Outperform | — |
| 25 Nov 2020 | Canaccord Genuity | Maintains | Buy | — |
| 22 May 2020 | B. Riley FBR | Downgrade | Neutral | — |
| 22 May 2020 | B. Riley Securities | Downgrade | Neutral | — |
| 15 May 2020 | Raymond James | Maintains | Outperform | — |
| 13 Mar 2020 | B. Riley FBR | Maintains | Buy | — |
| 13 Mar 2020 | B. Riley Securities | Maintains | Buy | — |
| 13 Mar 2020 | Stifel | Maintains | Buy | — |
| 4 Feb 2020 | Craig-Hallum | Initiates | Buy | — |
| 30 Jan 2020 | Cantor Fitzgerald | Assumes | Overweight | $59 → $14 |
| 22 July 2019 | Laidlaw & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for EOCN.
This page is one stock. Monday covers all of them.
EOCN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
EOCN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Eocene Ltd. returned −72.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
EOCN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.1×
- EV / EBITDA
- —
Cheaper than 95% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −68.2%
- Return on assets
- −30.2%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Eocene Ltd. has a market value of $1.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$11.3M.
Free cash flow in the twelve months to 30 June 2026: −$8.5M.
Eocene Ltd. employs 3 people.
Data provided by Twelve Data
EOCN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at EOCN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Eocene Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about EOCN
Is EOCN stock a buy right now?
Of the 1 analyst covering Eocene Ltd., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eocene Ltd. 11 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank EOCN?
As at 21 Nov 2026, Eocene Ltd. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (54 of 100).
What is the EOCN stock forecast for 2030?
No analyst covering Eocene Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EOCN are extrapolating price history, which says nothing about the business.
How has EOCN stock performed over the past year?
Eocene Ltd. returned -72.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Eocene Ltd. do?
Eocene Ltd. is an Israel-based biopharmaceutical and medtech company focused on gastrointestinal disease management and related therapeutic areas. The company develops pharmaceutical and device-based solutions for conditions such as liver disorders, gastrointestinal oncology, and colorectal care.
About Eocene Ltd.
Eocene Ltd. is an Israel-based biopharmaceutical and medtech company focused on gastrointestinal disease management and related therapeutic areas. The company develops pharmaceutical and device-based solutions for conditions such as liver disorders, gastrointestinal oncology, and colorectal care. Its portfolio includes Aramchol, an oral therapeutic candidate being developed for liver-related indications, as well as medical device technologies designed to support postoperative colorectal treatment. Eocene Ltd. combines research, clinical development, and product commercialization activities across its healthcare platform, with operations centered in Ramat Gan, Israel. The company serves a niche role in the biotechnology market by pursuing therapies and technologies aimed at unmet needs in gastrointestinal and adjacent medical fields.
CEO Mr. Allen Baharaff · 3 employees · Israel · https://eocn.com